Search

Your search keyword '"Ogasawara, S."' showing total 994 results

Search Constraints

Start Over You searched for: Author "Ogasawara, S." Remove constraint Author: "Ogasawara, S."
994 results on '"Ogasawara, S."'

Search Results

1. Optimization of RF phase and beam loading distribution among RF stations in SuperKEKB

3. INSPIRE: Challenge of 50 kg-class satellite to open up MeV gamma-ray astronomy

4. SuperKEKB operation using crab waist collision scheme

5. ESICM LIVES 2016: part two: Milan, Italy. 1–5 October 2016

6. 713P Pembrolizumab (Pembro) vs placebo (Pbo) as second-line treatment for sorafenib-treated advanced hepatocellular carcinoma (aHCC): 4.5-year follow-up from KEYNOTE-240

7. SO-13 Pembrolizumab in patients with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the open-label, phase 2 KEYNOTE-224 study

8. ESICM LIVES 2016: part one: Milan, Italy. 1-5 October 2016

9. 937P Multicenter phase II trial of lenvatinib plus hepatic intra-arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma: LEOPARD

10. 933P Updated results for pembrolizumab (pembro) monotherapy as first-line therapy for advanced hepatocellular carcinoma (HCC) in the phase II KEYNOTE-224 study

12. Abstract No. 37 LEAP-012 trial in progress: pembrolizumab, lenvatinib, and transarterial chemoembolization combination therapy for intermediate-stage hepatocellular carcinoma not amenable to curative treatment

17. Long-pulse Plasma Discharges by Upgraded ECH System in the LHD

20. 1016TiP LEAP-012 trial in progress: Pembrolizumab plus lenvatinib and transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC) not amenable to curative treatment

21. P-107 LEAP-012: A randomized, double-blind, phase 3 study of pembrolizumab plus lenvatinib in combination with transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma not amenable to curative treatment

22. Health-related quality of life (HRQoL) impact of pembrolizumab (pembro) versus best supportive care (BSC) in previously systemically treated patients (pts) with advanced hepatocellular carcinoma (HCC): KEYNOTE-240

26. True carcinosarcoma of the esophagus

34. Progress of ECRH by EBW in over-dense plasmas and controlling the confinement regime by ECCD with high power launching in LHD

35. Influence of high energy electrons on ECRH in LHD

36. Supplementary Material for: Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment

38. Pembrolizumab (Pembro) therapy vs best supportive care (BSC) in advanced hepatocellular carcinoma (HCC): KEYNOTE-240

42. Intracerebral hemorrhage in ICU: is it worth treating?

45. Analyses of intermediate stage hepatocellular carcinoma patients from the point of view of designing clinical trials comparing transarterial chemoembolization and systemic therapies

46. Temporal changes in recurrent incidences after curative therapies in early stage hepatocellular carcinoma

47. Verification of staging systems and treatment algorithms for hepatocellular carcinoma: perspectives from a Japanese field practice

48. Clinical features and prognosis of advanced stage hepatocellular carcinoma; verification of diverse progression processes

50. Transcriptome profiling of hepatitis B virus-infected human hepatocyte derived from chimeric mice with humanized liver

Catalog

Books, media, physical & digital resources